Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178254
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sandoval, Diego | - |
dc.contributor.author | Rama, Inés | - |
dc.contributor.author | Quero Ramos, Maria | - |
dc.contributor.author | Hueso Val, Miguel | - |
dc.contributor.author | Gómez, Francisco | - |
dc.contributor.author | Cruzado, Josep Ma. | - |
dc.date.accessioned | 2021-06-10T16:14:33Z | - |
dc.date.available | 2021-06-10T16:14:33Z | - |
dc.date.issued | 2021-01-18 | - |
dc.identifier.uri | http://hdl.handle.net/2445/178254 | - |
dc.description.abstract | Haemodialysis (HD) patients present more morbidity and mortality risk in coronavirus disease 2019 (COVID-19). In patients who may develop severe symptoms, the process called 'viral sepsis' seems to be a crucial mechanism. In those cases, the HD procedure provides an excellent tool to explore the benefit of some extracorporeal therapies. We reported the outcome of four HD patients with severe COVID-19 treated with Seraph®100 haemoperfusion (HP) device. Three of the four cases presented a good clinical response after HP. In conclusion, the treatment with Seraph®100 device may be a simultaneous treatment to improve HD patients with severe acute respiratory syndrome coronavirus 2. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfab010 | - |
dc.relation.ispartof | Clinical Kidney Journal, 2021, vol. 14, num. 5, p. 1475-1477 | - |
dc.relation.uri | https://doi.org/10.1093/ckj/sfab010 | - |
dc.rights | cc by-nc (c) Sandoval et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Hemodiàlisi | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Hemodialysis | - |
dc.title | Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-06-10T14:00:39Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33953913 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sfab010.pdf | 196.43 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License